• Skip to main content
  • Skip to footer

Accuronix

Developing novel cancer therapies

  • Home
  • Founders
  • Approach
  • Contact

Opening New Frontiers in Cancer Treatment

Accuronix develops novel therapies that selectively target cells and deliver cytotoxic payloads, thereby increasing efficacy and reducing toxicity risk

Learn More

Treating Rare Cancers with a Novel Platform

Platform Technology

Platform Technology

Targeting drugs to the σ-2 receptor is one of the most attractive cancer drug targeting strategies yet discovered.  Accuronix’s expertise in σ-2 will drive an expansion of our library of receptor ligands that can deliver multiple anti-cancer “warheads” to tumor cells.

Read More
Scientific Approach

Lead Candidate

ACXT-3102 is a novel small molecule drug conjugate in preclinical development for pancreatic adenocarcinoma, synovial sarcoma, and other rare tumors.  It employs Accuronix’s σ-2 technology to deliver a warhead that kills tumor cells  by promoting both apoptosis and ferroptosis, a newly recognized pathway for cancer cell death.

Read More
Partnerships

Partnerships

The substantial unmet needs in pancreatic cancer, coupled with the potential of ACXT-3102 in additional oncology indications, affords promising opportunities to achieve fast track and breakthrough designations.  We will pursue development of this candidate as well as follow-on opportunities through partnerships.

Read More

Footer

About Us

We are applying a novel drug-targeting technology to some of the most difficult problems in cancer therapy.

News & Publications
Financial Conflicts of Interest (FCOI)

Mission

With an initial focus in pancreatic cancer, the Company’s mission is to develop novel oncology therapies based on technology that selectively targets σ-2 receptors overexpressed on cancer cells

Partners

Washington University | University of Pennsylvania | BioGenerator

Contact Us

Accuronix Therapeutics
4340 Duncan Ave.
Suite 210
St. Louis, MO 63110

Contact
Bradley T. Keller, Ph.D.
President and CEO
[email protected]

Copyright © 2023 Accuronix.com · Powered by NeuConcept